BRIEF ARTICLE

Gemcitabine in elderly patients with advanced pancreatic cancer

Olivia Hentic, Chantal Dreyer, Vinciane Rebours, Magaly Zappa, Philippe Lévy, Eric Raymond, Philippe Ruszniewski, Pascal Hammel

Abstract

AIM: To assess feasibility, tolerability and efficacy of gemcitabine-based chemotherapy in patients ≥ 75 years old with advanced pancreatic cancer.

METHODS: All consecutive patients ≥ 75 years old with advanced pancreatic adenocarcinoma were included in this retrospective study. Necessary criteria to receive chemotherapy were: performance status 0-2, adequate biological parameters and no serious comorbidities. Other patients received best supportive care (BSC).

RESULTS: Thirty-eight patients (53% women, median age 78 years, range 75-84) with pancreatic cancer (metastatic: n = 20, locally advanced: n = 18) were studied. Among them, 30 (79%) were able to receive chemotherapy [median number: 9 infusions (1-45)]. Six patients (23%) had at least one episode of grade 3 neutropenia and one patient developed a grade 3 hemolytic-uremic syndrome. No toxic death occurred. Three patients (11%) had a partial tumor response, 13 (46%) had a stable disease and 12 (43%) had a tumor progression. Median survival was 9.1 mo (metastatic: 6.9 mo, locally advanced: 11.4 mo).

CONCLUSION: Tolerance and efficacy of gemcitabine-based chemotherapy is acceptable in elderly patients in good condition, with similar results to younger patients.

© 2011 Baishideng. All rights reserved.

Key words: Elderly; Pancreas; Cancer; Gemcitabine

INTRODUCTION

Although pancreatic cancer (PC) only accounts for 2% of all cancers, it is the fourth leading cause of cancer death in the United States (US)[1]. Prognosis is very poor, with an estimated incidence of 33,000 per year in the US and a similar death incidence rate[1]. Median survival in patients with advanced PC who receive the best support-
ive care (BSC) is only three to four months. Chemotherapy with gemcitabine has been considered the standard treatment of non-resectable PC since the study by Burris et al[3]; it slightly improves both survival and clinical response and is acceptably tolerated. Several drugs have been tested in combination with gemcitabine but with disappointing results. The only combination that showed a slight but significant increase in survival was erlotinib and gemcitabine in a study by Moore et al[9].

PC usually occurs in elderly patients. In the US, the incidence rate adjusted by age and for 100,000 is of 64.2 over 65 years old and of 3.7 under 65 years old[10]. In France 37.1% of PC cases occur in patients ≥ 75 years old[11]. Survival rates in this subgroup of patients seem to be shorter than in younger patients[12]. Physicians may hesitate to offer intravenous chemotherapy because of frequent comorbidities and short estimated survival; in addition, the motivation of elderly patients for this type of treatment should be carefully assessed. Nevertheless, it has clearly been shown that elderly patients are under-represented in cancer trials[8,13]. The efficacy and tolerance of chemotherapy in elderly patients with colorectal cancer has been shown in previous studies[8-12]. Most phase III studies of chemotherapy for PC include results of, but do not specifically analyze, the subset of patients ≥ 70-75 years old[2,13-15]. Results by Maréchal et al[16] in a pooled analysis of patients ≥ 70 years old who were included in seven prospective phase 2 or phase 3 studies testing various gemcitabine-based first line combinations, suggest that chemotherapy is feasible in the elderly as well as in younger patients with PC. Likewise, Locher et al[17] supported the use of gemcitabine in another study in elderly patients.

The aim of this retrospective monocentric study was to assess feasibility, tolerance and efficacy of gemcitabine-based palliative chemotherapy in patients ≥ 75 years old treated for PC.

MATERIALS AND METHODS

Selection of patients

All patients with digestive cancer in our hospital are discussed at the weekly multidisciplinary oncological committee meeting, even if they are only able to receive best supportive care on first intention. For the current study, all patients with pathologically-proven advanced adenocarcinoma of the exocrine pancreas who were ≥ 75 years old and listed in our database were considered. Patients with adenocarcinoma of the ampulla or the biliary tract were excluded. Overall, 40 patients were included for this retrospective analysis. Among them, 2 patients were excluded as they received gemcitabine in another institution (West Indies) and thus follow-up was not possible. Finally, 38 consecutive patients fulfilling these criteria and who were treated in our hospital between March 2000 and June 2006 were retrospectively studied. After clinical and imaging assessment, tumors were classified as locally advanced (stage III) or metastatic (stage IV) according to the UICC classification (UICC).

Criteria required to propose chemotherapy were an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 and no serious comorbidities. Before starting chemotherapy, pain and biliary obstruction had to be controlled and adequate biological parameters (i.e., neutrophil count > 1500/mL, platelet count > 100,000/mL, serum creatinine < 1.5 × the upper limit of normal value (ULN), alkaline phosphatase < 5 × ULN, and bilirubin < 1.5 × ULN) were required. If one of these criteria was not fulfilled, BSC was decided.

Treatment

Chemotherapy included gemcitabine as a single agent according to the Burris regimen (gemcitabine 1000 mg/m² as a 30-min infusion weekly for 7 out of 8 wk and then for 3 out of 4 wk)[2] or combined with oxaliplatin according to the GemOx regimen (gemcitabine 1000 mg/m² as a 100-min infusion on day 1 and oxaliplatin 100 mg/m² as a 2-h infusion on day 2 every 2 wk)[18].

Patients who received at least one infusion of chemotherapy were placed in the “chemotherapy group”. All the other patients received BSC.

Chemotherapy was stopped if there was an unacceptable/life-threatening adverse event, if performance status worsened (i.e., ECOG ≥ 3) and/or if tumor progression occurred according to imaging results. The type of chemotherapy, the number of infusions and the reason why chemotherapy was not administered or was stopped were analysed.

Safety and efficacy evaluation

Baseline assessment included medical history, physical examination with an evaluation of clinical symptoms, and biological analyses (blood cell count, serum creatinine, bilirubin, ASAT, ALAT, alkaline phosphatase). During the treatment period, blood tests, toxicity evaluation and a physical examination were performed before each infusion.

Toxicity was graded according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 2. Chemotherapy was delayed if the grade of toxicity ≥ 2; the dose of gemcitabine was reduced by 20% if the toxicity grade was ≥ 3.

Tumor response was assessed by computed tomography scan at three month intervals according to RECIST (Response Evaluation Criteria In Solid Tumors)[19]. Evaluation procedures were performed ahead of schedule if the patient’s general condition worsened or severe toxicity occurred. Overall survival (OS) was calculated from the day of diagnosis of non-resectable PC to the date of death. This study was proposed after the agreement of our institution review board.

Statistical analysis

Qualitative data are expressed as numbers and percentages. Quantitative data are expressed as median (range).
Survival was determined by the Kaplan-Meier method.

RESULTS

General characteristics
Twenty women and 18 men were studied. Median age was 78 years old (75-84). Tumors were metastatic in 20 patients (including tumor relapse after surgical resection in five patients) and locally advanced in 18 patients. Median follow up was 7 mo (1-44) (Table 1). Thirty of the 38 patients (79%) received gemcitabine-based chemotherapy (single agent: \( n = 28 \), combined with oxaliplatin: \( n = 2 \)) with a median of 9 infusions (1-45). Twenty-four patients (83%) completed at least 2 mo of chemotherapy (i.e., 7 infusions). The relative dose-intensity of gemcitabine was 83%. Chemotherapy was stopped due to tumor progression (\( n = 21 \)), toxicity (\( n = 1 \)) or fatigue (\( n = 4 \)); it was replaced by chemoradiotherapy (\( n = 2 \)) in patients with controlled disease. The eight remaining patients did not receive chemotherapy due to exclusion criteria (\( n = 5 \)) or a life-threatening medical event that occurred after the decision to treat but before the beginning of the treatment (\( n = 3 \)) (Table 2).

Safety evaluation
Tolerance data were available in 26 of 30 patients. Six patients (23%) had at least one episode of grade 3 hematological toxicity (neutropenia). One patient developed grade 3 hemolytic-uremic syndrome, so gemcitabine was discontinued. No grade 4 toxicity or toxic deaths occurred.

Tumor response rate
Response rate was available in 28 of 30 patients. During the first assessment (at 3 mo), 3 patients (11%) had partial tumor response (PR), disease was stable in 13 (46%) (SD) and 12 (43%) had tumor progression (PD). For 14/15 patients with metastatic PC, 1 PR (7%), 4 SD (29%) and 9 PD (64%) were observed. Second line treatment included chemotherapy in four patients with progressive disease (GemOx after gemcitabine alone: \( n = 3 \), and Foliri after GemOx: \( n = 1 \)), and chemoradiotherapy was proposed in two 75-year old patients with locally advanced tumors who were in very good condition with controlled tumors after 3 mo of chemotherapy. The latter treatment involved irradiation of 50.4 Gy with a continuous infusion (200 mg/m²) of 5-fluorouracile as a radiosensitizer based on the results of a previous study[20].

Overall survival
Median survival of all patients (\( n = 38 \)) was 8.9 mo and the one-year survival rate was 33.2%. Median survival of the 8 patients who received BSC was 2.95 mo. In patients receiving chemotherapy, median survival was 9.1 mo; this was 6.9 mo in patients with metastatic cancer and 11.4 mo in patients with locally advanced cancer; the 1-year survival rate was 40.6% and 44%, respectively. Overall survival in patients treated with gemcitabine-based chemotherapy according to disease stage is presented in Figure 1.

DISCUSSION
Although a direct comparison was not performed, this monocentric retrospective study suggests that the safety and efficacy of gemcitabine-based chemotherapy in elderly patients is similar to that in younger patients.
Most eligible patients (79%) received a median of 9 infusions of chemotherapy. Safety was acceptable with grade 3 neutropenia in 23% of patients (with no grade 4), and one case of grade 3 hemolytic-uremic syndrome requiring treatment discontinuation. There were no toxic deaths. These safety results are similar to those in randomised studies including younger patients which report neutropenia as the most frequent type of toxicity with gemcitabine (grade 3-4 toxicities from 9% to 27.6%)[2,3,13-15,18].

In our study, disease control was obtained in 57% of patients (PR: 11% and SD: 46%) who received chemotherapy, which compares favourably to other published randomised studies (41.2% to 52.8%)[2,3,13,21]. The objective response rates in these studies, which include patients with both locally advanced and metastatic cancers, was 7.1% to 17.3%[3,14,15,18]. The survival rate in our study was 9.1 mo in patients who received chemotherapy; this was 6.9 mo in patients in the metastatic subgroup and 11.4 mo in the locally advanced subgroup. The 1-year survival rate of patients with metastatic and locally advanced disease who received chemotherapy was 40.6% and 44%, respectively. In the randomised series with younger patients, median survival rates in the gemcitabine arm were 5.6 and 7.2 mo, respectively[2,3,13-15,18,21].

These results should be cautiously interpreted since methodological biases are inevitable in such a retrospective study. In addition, it was conducted in a tertiary care institution, thus our population should not entirely reflect the “true life” practice for elderly patients with PC. Likewise, our study does not allow distinguishing of the potential influence of performance status (i.e., 0-1 vs 2) on both treatment safety and efficacy.

One retrospective phase II trial analysed the impact of age (< or ≥ 65 years) on the efficacy and tolerance to gemcitabine in advanced non-small cell lung cancers. Hematological, non-hematological toxicities and dose reductions, or the mean number of cycles were similar in both age groups[22].

A recent study by Locher et al[23] reported 39 patients ≥ 70 years old with PC treated by a fixed-dose rate of gemcitabine[23]. The authors showed a good efficacy of this treatment with a clinical benefit observed in 20%, a tumor response rate in 10% and a stabilization of the disease in 53% of patients. The median survival was 10 mo and the time to progression was 7 mo. Grade 3-4 neutropenia and alopecia occurred in respectively 38% and 18%. These side-effects were higher than in others trials probably due to the fixed dose rate of gemcitabine[2,3,13-15,18,23]. Maréchal et al[25] analyzed 42 patients > 70 years old pooled from seven prospective studies evaluating gemcitabine-based chemotherapy and compared them to 57 younger patients. Two thirds of the elderly patients received gemcitabine alone and one third received gemcitabine-based combinations (mainly gemcitabine-oxaliplatin). The median overall survival (220 d vs 240 d), time to progression (104 d vs 119 d), response rate (4.8% vs 8.9%) and clinical benefit (57.1% vs 59.6%) were similar in elderly and non-elderly patients. Tolerance to chemotherapy was acceptable in the elderly group despite a dose reduction or delay in therapy in 62%, a higher figure than that observed in our study. As in our study, neutropenia was the most common cause of grade 3-4 toxicity. Grade 3-4 neutropenia, anaemia and peripheral neuropathy occurred more often in the elderly group than in younger patients (30.9% vs 8.8%, 14.3% vs 8.8% and 4.8% vs 0% respectively). Age was not an independent prognostic factor in multivariate analysis of the whole population. Multivariate analysis identified ASAT and Karnofsky index as independent prognostic factors in the elderly group[26].

A Japanese study specifically reported results in 25 patients ≥ 70 years old receiving gemcitabine 800-1000 mg/m² compared to 43 patients receiving BSC. Patients receiving chemotherapy had a more favourable prognosis and acceptable tolerance[27]. Another retrospective study by Nakachi et al[28], presented in abstract form at the ASCO GI meeting in 2007, suggested that gemcitabine was effective and well tolerated in selected elderly patients. Thirty-seven patients ≥ 75 years old were compared to 137 younger patients. Grade 3-4 neutropenia (18.9% vs 19 %) and tumor response rates (8.1% vs 4.3%) were similar. In contrast, median overall survival was better in the elderly group (8 mo vs 5.6 mo, P = 0.009).

Recently, the promising schema FOLFIRINOX (5-fluorouracil, irinotecan and oxaliplatin) was shown to be superior to gemcitabine in terms of tumor response and overall survival[29]. However, patients treated in this study were less than 75 years-old and in very good condition (PS 0-1). Moreover, significant toxicity was seen [45.7% of patients experienced a significant (grade 3-4) hematological toxicity with 5.4% of febrile neutropenia] that could be problematic in elderly patients[29]. Further studies are warranted in latter patients using such drugs.

In conclusion, gemcitabine chemotherapy seems to be effective and safe in elderly patients with PC in good condition. The risk/benefit ratio of this treatment should be discussed in a multidisciplinary context and these patients should actively participate in therapeutic decisions. Prospective studies of this specific subgroup of patients with PC are needed.

ACKNOWLEDGMENTS

The authors thank Pr. Christophe Louvet for his critical review of this manuscript.

COMMENTS

Background

Pancreatic cancer is a severe disease that is often treated using systemic chemotherapy as it is non-resectable in up to 80% of patients at the time of diagnosis. Significant rates of patients with this disease are older than 75 years. However, most phase III studies of chemotherapy for pancreatic cancer include elderly patients, but they do not provide a specific analysis of patients ≥ 70-75 years old. Thus, this specific population is strongly underrepresented in therapeutic trials for digestive cancers and thus guidelines for clinical practice are lacking. In this paper, the results suggest that elderly patients with pancreatic cancer should be considered for systemic chemotherapy. However, further studies are needed to confirm these findings and to evaluate the optimal treatment strategies for this population.
cancer, when they are in acceptable condition, could receive gemcitabine-based chemotherapy which is safe and seems to be as efficient as in younger patients. 

Research frontiers
Tumor response rates, toxicity and duration of tumor control were specifically analyzed in a homogeneous population of 38 elderly patients with pancreatic cancer treated in one center.

Innovations and breakthroughs
This is a homogeneous study of consecutive patients treated by an experienced team in digestive cancers, particularly pancreatic cancer. The authors have shown that toxicity of gemcitabine was manageable, and tumor control and overall survival were encouraging, as they appear to be similar to that of younger patients. The authors hope it will encourage physicians to evaluate and consider chemotherapy in such patients.

Applications
It is time to pave the way of chemotherapy in elderly patients with pancreatic cancer knowing that a significant subset of them may benefit from these treatments. In the future, patients should be better selected for the treatments using molecular markers (i.e., hENT-1 expression and gemcitabine).

Terminology
A locally advanced pancreatic cancer is a tumor involving the arterial axis (celiac trunk, mesenteric artery) and thus is non-resectable despite there being no detectable metastases. This form of cancer should be distinguished from metastatic tumors as the prognosis is different (slightly better, and some patients can return to surgical treatment in cases of good tumor response after chemotherapy), and thus separate analyses are needed.

Peer review
This is an article describing gemcitabine in elderly patients with advanced pancreatic cancer.

REFERENCES
1 Jamal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249
2 Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Criggs MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413
3 Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawka P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Psaty M, Parulekar W, Eroltinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966
4 SEER Cancer Statistics Review, 1975-2005. In: Ries LAG, Melbert D, Krapcho M, Neyman N, Aminou R, Herlihy D, Hellman S, Schrag D, editors. National Cancer Institute. Bethesda, MD. Available from: URL: http://seer.cancer.gov/csr/1975_2005/
5 Bolot A, Grosclaude P, Bossard N, Jouga E, Benhamou E, Delafosse P, Guizard AV, Molinie F, Danzon A, Bara S, Bouvier AM, Trémare C, Binder-Fourcade F, Colonna M, Daubisse L, Hédelin G, Lawaute G, Stangl N, Maynadie M, Monneraud A, Troussard X, Faivre J, Collignon A, Janoray I, Arveux P, Buemi A, Raverdy N, Schwartz C, Bovet M, Chéné-Chatallie L, Estève J, Remontet L, Velten M. Cancer incidence and mortality in France over the period 1980-2005. Rev Epidemiol Sante Publique 2008; 56: 159-175
6 Hutchins LF, Unger JM, Crowley JJ, Colman CA, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341: 2061-2067
7 Yee KW, Pater J, Pho L, Zee B, Sù L. Enrolment of older patients in cancer treatment trials in Canada: why is age a barrier? J Clin Oncol 2003; 21: 1618-1623
8 Aparicio T, Desrémé J, Lecomte T, Mitry E, Bellco J, Etienne I, Montembault S, Vayre L, Locher C, Ezenis J, Artru P, Malbré M, Domiguez S. Oxaalpinatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly. Br J Cancer 2003; 89: 1439-1444
9 Aparicio T, Mitry E, Sa Cunha A, Girard L. [Management of colorectal cancer in elderly patients]. Gastroenterol Clin Biol 2005; 29: 1014-1023
10 Goldberg RM, Tabah-Fisch I, Bleiberg H, de Gramont A, Tournigand C, Andre T, Rothenberg ML, Green E, Sargent DJ. Foiled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006; 24: 4085-4091
11 Magne N, François E, Broisin L, Guardiola E, Ramalioi A, Ferrero JM, Name M. Palliative 5-fluorouracil-based chemotherapy for advanced colorectal cancer in the elderly: results of a 10-year experience. Am J Clin Oncol 2002; 25: 126-130
12 Popescu RA, Norman A, Ross PJ, Parikh B, Cunningham D. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 1999; 17: 2412-2418
13 Colucci G, Labianca R, Di Costanzo F, Gobbia V, Carteni G, Massida B, Dapretto E, Manzione L, Pizzicato S, Ciampicen M, Cavanna L, Gualani F, Maiello E, Testa A, Pedezolli P, Falcioni M, Callo G, Di Maio M, Perrone F. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 2010; 28: 1645-1651
14 Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, Harper PG, Dunn J, Tudor-Smith C, West J, Falk S, Crellin A, Adah F, Thompson J, Leonard P, Ostrowski KJ, Eaton M, Scheithauer W, Herrmann R, Neoptolemos JP. Phase III randomized comparison of gemcitabine versus gemcitabine plus capcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009; 27: 5513-5518
15 Herrmann R, Bodoky G, Ruhstaller T, Glmellus B, Bajetta E, Schuller J, Saletti P, Bauer J, Figer A, Pestalozzi B, Köhne CH, Mingrone W, Stennet SM, Tâmas K, Korneg GV, Koeberle D, Cina S, Bernhard J, Dietrich D, Scheithauer W. Gemcitabine plus capcitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007; 25: 2212-2221
16 Mariéchal R, Demos A, Gay F, de Maertelaer V, Arvanitaki M, Hendrise A, Van Laethem JL. Tolerance and efficacy of gemcitabine and gemcitabine-based regimens in elderly patients with advanced pancreatic cancer. Pancreas 2008; 36: e16-e21
17 Locher C, Fabre-Guillemin E, Brunetti F, Auroux J, Delchier JC, Piedbois P, Zelek E. Fixed-dose rate gemcitabine in elderly patients with advanced pancreatic cancer: an observational study. Crit Rev Oncol Hematol 2008; 68: 178-182
18 Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, Zaniuloni A, Dureau M, Attini E, Tahlé J, Faroux R, Lepere C, de Gramont A. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23: 3509-3516
19 Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian M, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216
20 Huguet F, André T, Hammel P, Artru P, Baloso J, Selle F, Deniaud-Alexandre E, Ruzniewski P, Touboul E, Labianca R, de Gramont A, Louvet C. Impact of chemoradiotherapy
after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007; 25: 326-331

21 Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schönekäs H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A, Wilkowski R. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006; 24: 3946-3952

22 Shepherd FA, Abratt RP, Anderson H, Gatzemeier U, Anglin G, Iglesias J. Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer. Semin Oncol 1997; 24(Suppl 7):50-55

23 Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003; 21: 3402-3408

24 Hanada K, Hino F, Amano H, Fukuda T, Kuroda Y. Current treatment strategies for pancreatic cancer in the elderly. Drugs Aging 2006; 23: 403-410

25 Nakachi K, Furuse J, Ishii H, Suzuki E, Shimizu S, Yoshino M. Tolerability and efficacy of standard chemotherapy with gemcitabine for elderly patients with advanced pancreatic cancer. Gastrointest Cancer Res 2007; 1: 73

26 von der Thüalen T, Simon R, Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachel JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducrèux M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825